Trillium appoints Biogen CSO to board
This article was originally published in Scrip
Trillium Therapeutics, a Canadian biopharmaceutical company developing therapies for immune-mediated conditions, has appointed Dr Michael Gresser to its board of directors. Dr Gresser previously served as vice-president of research inflammation with Amgen, and was involved in the discovery of molecules for the products Singulair (montelukast) and the withdrawn anti-inflammatory Vioxx (rofecoxib). He is currently chief scientific officer of Oxford BioTherapeutics, a role he has held since late 2009.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).